Shelly Mui-Lipnik

Executive Director, Tax Policy & Federal Government Affairs

Novartis

Shelly is the tax policy and government affairs principal for Novartis. Her tax portfolio focuses on international, federal and state level. Shelly is also the Novartis lead working closely with GBA (formerly OFII), BIO and the U.S. Chamber in addition to leading inbound pharma coalition. As part of her portfolio, she manages the company’s engagement on appropriations, Committee on Foreign Investment in the United States (CFIUS), lobbying disclosures and campaign finance. Additionally, Shelly leads Novartis’ data and digital/AI public affairs function in the U.S. which includes addressing cross-cutting issues such as ethics, bias, privacy, intellectual property and workforce training.

Prior to Novartis, Shelly was lead policy staff on tax, securities, and accounting policy issues impacting biotechnology companies. During her time at BIO, Shelly worked closely with several members of Congress across several House and Senate committees. Shelly’s expertise includes IRC Section 385 Debt-Equity regulations, R&D tax credit, orphan drug tax credit, therapeutic discovery tax credit and innovation incentives in the tax debate. She has also worked on Securities Exchange Commission (SEC) regulations regarding short-selling, Financial Accounting Standards Board (FASB) regulations regarding revenue recognition, and financial services legislation encouraging capital formation.

Shelly has also worked on employee benefits policy issues in Aon Hewitt Associates’ Washington office. In addition, Shelly worked on Title I of ERISA on behalf of the U.S. Department of Labor for several years.

Shelly received a Masters in Taxation (LL.M.) and a Certificate in Employee Benefits from Georgetown University Law Center, a Juris Doctorate from Syracuse University College of Law, and a Bachelor of Science in International Business from the University of Maryland. She is a member of the New York Bar and the District of Columbia Bar.